Extrawell Pharmaceutical Lifts Stake in Key Subsidiary via Share Buy-Back

Extrawell Pharmaceutical Holdings Limited ( (HK:0858) ) just unveiled an announcement.

Extrawell Pharmaceutical Holdings Limited has completed a share buy-back and cancellation at its 80.46% indirectly owned subsidiary Changchun Extrawell, following fulfillment of all conditions on 16 March 2026. After the transaction, Changchun Extrawell’s issued shares were reduced from 45,430,000 to 40,860,000 and its registered capital decreased from RMB45.43 million to RMB40.86 million.

As a result of the share cancellation, the Group’s equity interest in Changchun Extrawell has risen from 80.46% to 89.46%, while minority shareholders now hold the remaining 10.54% split among three investors. Changchun Extrawell remains a non-wholly owned subsidiary, and its earnings, assets and liabilities will continue to be fully consolidated into the Group’s financial statements, slightly strengthening Extrawell’s control and economic interest without altering its consolidation status.

The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.08 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.

More about Extrawell Pharmaceutical Holdings Limited

Extrawell Pharmaceutical Holdings Limited is a Bermuda-incorporated investment holding company listed in Hong Kong, operating through subsidiaries in the pharmaceutical sector. The Group focuses on developing, manufacturing and distributing pharmaceutical products in mainland China, with Changchun Extrawell as one of its key non-wholly owned operating subsidiaries.

Average Trading Volume: 2,448,421

Technical Sentiment Signal: Sell

Current Market Cap: HK$204M

For a thorough assessment of 0858 stock, go to TipRanks’ Stock Analysis page.